UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 2514, ~~2019~~2021

NANO MOBILE HEALTHCARE, INC.

(Exact Name of Registrant as Specified in its Charter)

Delaware (State or other ~~jurisdiction~~jurisdictionof of incorporation) 000-55155 (~~Commission~~CommissionFile ~~File~~ Number) 98-0659770 (I.R.S. ~~Employer~~EmployerIdentification ~~Identification~~ No.)

One Boston Place Suite 2600
Boston, MA 02108
(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: (~~617~~877) ~~336~~626-~~7001~~6681

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, par value of $0.00001

VNTH

OTCMKTS

Item 1.01. Entry into a Material Definitive Agreement

On October 14, 2021, pursuant to an effective Settlement Agreement, for undisclosed amount, the Company bought back the Convertible Notes that previous managements sold to VVIS VIRES GROUP, INC. (“VVG”), a corporation formed and existing pursuant to the laws of the State of New York and having a principal place of business located at 111 Great Neck Road, Suite 216, Great Neck, New York 11021.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

On October 2514, ~~2019~~2021 ~~Joseph~~Frank C.I ~~Peters~~Igwealor resigned as as a member of the Board of Directors (the “"Board”") of Nano Mobile Healthcare (the “"Company”"), effective as of the date of such resignation. Mr. ~~Peters~~Igwealor also resigned as Chairman of the Board and Chief Executive Officer of the Company effective as of such date. Mr. ~~Peters’~~Igwealor's resignation was not the result of any dispute or disagreement with the Company or the Company’'s Board of Directors on any matter relating to the operations, policies or practices of the Company.

~~Robert~~David Noah ~~Chicoski~~Kittle has been appointed the ~~interim~~ President and CEO for the Company effective October 2514, ~~2019~~2021.

2Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description

2.1		10.15.2021 Press Release
10.1		10.14.2021 Settlement Agreement

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NANO MOBILE HEALTHCARE, INC.

Date: October 25, 2019	By: /s/ Robert Chicoski
Date: October 15, 2021	By: /s/ David N Kittle
	Name:	~~Robert~~David ~~Chicoski~~N Kittle
	Title:	~~Chief~~President ~~Financial Officer~~ and ~~Interim~~ CEO

Filing Compare · Nano Mobile Healthcare, Inc.